Scientific Advisors

About Us

Philip S. Schein, M.D., Chief Scientific Advisor image

Dr. Philip Schein is widely regarded as a leading international authority in the treatment of cancer. Currently he a Visiting Professor in Cancer Pharmacology, University of Oxford and as President of The Schein Group, which provides consultative services to the pharmaceutical industry. Dr. Schein served as a Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch, National Cancer Institute. His next appointment was at the Georgetown University School of Medicine in Washington, DC, as Professor of Medicine and Pharmacology, Chief of Medical Oncology and Scientific Director of the Vincent T. Lombardi Cancer Research Center. Subsequently he served as Vice President of Worldwide Clinical Research and Development, and Director of the Laboratory of Molecular Oncology, SmithKline & French Laboratories, where he had responsibility for all SK&F clinical research and development activities.  In 1987 Dr. Schein founded U.S. Bioscience, a publically-traded pharmaceutical company focused on cancer and AIDS, and while serving as Chairman and CEO he took three products, Ethyol, Hexalen and Neutrexin, through development and regulatory approval in the US, Europe, Canada and other countries. 

Dr. Schein has held major positions in the field of Medical Oncology. He has served as President of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration’s Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. He has also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research. In 1984, in a survey of department chairmen and clinical-program chiefs at 87 medical schools, Dr. Schein was ranked as one of the 120 best doctors in America, and one of four listed in Oncology. 

He has authored over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents.  He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education. Dr. Schein is a Fellow of the Royal College of Physicians of London and the Royal College of Physicians and Surgeons at Glasgow. While serving as CEO of U.S. Bioscience he was the 1992 recipient of the Delaware Valley’s Entrepreneur of the Year Award in the “Emerging Company” category, and in 1995 the region’s 3rd Annual Enterprise Awards designated U.S. Bioscience the “Technology Transfer Company of the Year.” He has been awarded a Honorary Doctor of Science degree from Rutgers University and a Doctorate Honoris Causa from the National University of Rosario, Argentina.  He serves on the Board of Directors of Medicis, and on the scientific advisory boards of several companies in the biotechnology/pharmaceutical industry.


Scott Gottlieb, M.D.image
Resident Fellow, American Enterprise Institute;
Former Deputy Commissioner for Medical and Scientific Affairs, U.S. Food and Drug Administration

Scott Gottlieb, MD is currently a practicing physician and Resident Fellow at the American Enterprise Institute (AEI), a private, nonpartisan, not-for-profit institution dedicated to research and education on issues of government, economics and social welfare.

From 2005-2007, Dr. Gottlieb served as FDA Deputy Commissioner and before that, from 2003-2004, as a senior advisor to FDA Commissioner Mark McClellan and as the FDA’s Director of Medical Policy Development. He left FDA in the spring of 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of Medicare and Medicaid Services, where he supported the agency’s policy work on quality improvement and coverage and payment decision-making, particularly related to new medical technologies.
Dr. Gottlieb is the author of more than 300 articles that have appeared in leading medical journals as well as The Wall Street Journal, The York Times, USA Today and Forbes Magazine. Dr. Gottlieb has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on the cable financial news channel CNBC.
Dr. Gottlieb completed his residency in internal medicine at the Mount Sinai Hospital and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Connecticut.  Dr. Gottlieb practices medicine as an attending physician at Stamford Hospital in Connecticut where he is an internist on the hospital’s inpatient medical wards.

Articles and Short Publications by Scott Gottlieb (list by AEI)

Emil J. Freireich, M.D., D.Sc. image

Emil J. Freireich, M.D., D.Sc., Director of the Adult Leukemia Research Program, has made innovated and pioneering contributions to M. D. Anderson and the medical community at large since arriving at the hospital in 1965. Board certified in Internal Medicine, Dr. Freireich treats patients with all types of leukemia. Since receiving his M.D. degree (with honors) from the University of Illinois College of Medicine and joining M. D. Anderson as an Internist and Professor of Medicine, Dr. Freireich has made significant advancements in the treatment of cancer, especially with developments of therapies and techniques for clinical research. Throughout his career at M. D. Anderson, Dr. Freireich has served as Head of the Department of Developmental Therapeutics from 1972-83 and Chairman of the Department of Hematology from 1983-85 and has authored/co-authored over 575 articles on cancer therapeutics and research. He has also been a member of several medical societies, editorial boards, and local, state, and national medical organizations. He has served as President of the American Society of Clinical Oncology.  In addition to his contributions as a medical doctor and researcher, Dr. Friereich also enhances the medical profession as a professor, teaching young medical oncologists at the University of Texas Medical School at Houston and the University of Houston. In recognition of his achievements, Dr. Freireich has received many awards and honors, including the E.J. Cogn-D.G.P. de Laval Award for Scientific Contribution to Apheresis in 1994.

(From the Director:  This tribute and analysis of Dr. Freireich’s contributions to drug development was written more than ten years ago and his contributions have only grown since then.)
Drug Development in Solid Turmors: Personal Perspective of Dr. Emil J. Freireich’s Contributions

Paul F. Schellhammer, M.D., F.A.C.S. image

Dr. Paul Schellhammer received his undergraduate education at the University of Notre Dame and his medical school training and Cornell Medical College in New York City. His surgical and urologic training were taken at the University Hospital of Cleveland in Cleveland, Ohio and the Medical College of Virginia, Richmond, Virginia. This was followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Subsequently he joined the practice of Devine Poutasse Fiveash Urology and became a faculty member of Eastern Virginia Medical School where he eventually achieved the rank of Professor and then also served as Chairman of the Department of Urology and Program Director of the Resident Training Program.

Dr. Schellhammer has made many contributions to the field of urologic oncology and published widely in that discipline, especially in prostate cancer. He serves on several editorial boards, and has served as a trustee of the American Board of Urology as its President. He has also served as President of the Society of Urologic Oncology,
as President of his Mid-Atlantic Section of the American Urologic Association, as a member of the Board of Directors of the American Urologic Association, and has been elected President of the American Urologic Association in the year 2007.

Barbara J. Scheffler

Barbara J. Scheffler is President of The Scheffler Group, Inc., a consulting company specializing in worldwide clinical drug development and regulatory submissions. Ms. Scheffler graduated Summa Cum Laude with a Bachelors degree in mathematics and a Masters degree in statistics from The Pennsylvania State University. She is a member of Phi Beta Kappa and Phi Kappa Phi, the mathematics honor society.  Ms. Scheffler has over 30 years of experience in drug development in the Pharmaceutical Industry, primarily in the area of oncology. 

Prior to forming The Scheffler Group, Ms Scheffler was a Sr. Vice President at U.S. Bioscience, Inc., a pharmaceutical company dedicated to the development of therapeutics for the management of cancer and allied diseases such as AIDS.  Her responsibilities included the development and management of both Clinical Operations and Regulatory Affairs Departments. Ms. Scheffler played a pivotal role in successful filing and prosecution of several New Drug Applications with the FDA, the EMEA and the Canadian HBP, including Ethyol, Neutrexin and Hexalen. Ms. Scheffler also worked at Smith Kline and French Laboratories, initially as a project statistician and then assuming increasing responsibilities for regulatory affairs and management, and played a key role in the approval of auranofin.

David Alberts, M.D.image

Dr. David Alberts is the Director of the Arizona Cancer Center and a world leader in the field of cancer prevention research.  After training at the NCI serving on the faculty and at the University of California, San Francisco, he moved in 1975 from UCSF to the University of Arizona Cancer Center, where he served as Director of the Cancer Prevention and Control Program from 1989 to 2005. The hallmark of his research career has been to take promising anticancer and chemopreventive agents from basic studies of their pharmacology all the way to the clinic. 

Dr. Alberts has made numerous contributions beyond his own research to advancing the cause of cancer prevention. He has served as the Chair of the FDA’s Oncologic Drug Advisory Committee (1982-1984), was a member of the NCI’s Board of Scientific Advisors (1997-2006), is Co-Editor-in-Chief of Cancer Epidemiology, Biomarkers and Prevention (2002-2007), and Chairs the Cancer Prevention and Control Committee in the Gynecologic Oncology Group (1995-present). He received the American Society of Clinical Oncology ACS Cancer Prevention Award in 1999, the American Association for Cancer Research Joseph Burchenal Eighth Annual Award for Excellence in Clinical Research in 2003 and the American Society of Preventive Oncology Distinguished Career Award in 2003. In 2004, Dr. Alberts received the third annual AACR-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research which is given annually to a scientist residing in any country in the world for his or her seminal contributions to the field of cancer prevention. Research must have had not only a major impact on the field, but must also have stimulated new directions in this important area.

A list of Dr. Alberts’ related publications will be available on the website shortly and is currently available upon request.

Joseph Bertino, M.D.image

Dr. Joseph R. Bertino is the Associate Director of the Cancer Institute of New Jersey, at the Robert Wood Johnson School of Medicine in New Brunswick, and a Professor of Medicine and Pharmacology and University Professor at UMDNJ-Robert Wood Johnson Medical School. He serves on the Board of Directors of the Lymphoma Research Foundation and is the past Chair of the Scientific Advisory Board. Dr. Bertino received his undergraduate degree from Cornell University in 1950 and his medical degree from Downstate Medical Center in Brooklyn, New York in 1954. His postdoctoral training included serving as a research fellow at the Division of Hematology and Biochemistry at the University of Washington School of Medicine (1958-61). In 1961 Dr. Bertino was appointed Assistant Professor in the Departments of Pharmacology and Medicine at Yale University School of Medicine, where he advanced through the academic ranks to Professor in 1969. At Yale, he also served as Chief of Oncology and Chemotherapy (1966-86) and Associate Director for Clinical Research at Yale Comprehensive Cancer Center (1979-86). In 1986, he moved to Memorial Sloan-Kettering Cancer Center where he served as Chairman of the Molecular Pharmacology and Therapeutics Program, and Attending on the Lymphoma Service. On January of 2002, he left MSKCC to accept his present position at the Cancer Institute of New Jersey.

Dr. Bertino has been an American Cancer Society Professor since 1976. During his academic career, he has received numerous awards and honors for his research accomplishments including the Rosenthal Award form the American Association of Clinical Research, the Karnofsky Award form the American Society for Clinical Oncology, and the American Cancer Society Medal of Honor. He has served on numerous committees, study sections and editorial boards. He was the founding editor of the Journal of Clinical Oncology. Currently, he is associate editor for several journals, including Cancer Research and Clinical Cancer Research and he is the editor of the Encyclopedia of Cancer. Dr. Bertino served as the President of the American Association for Cancer Research from 1995-96, and is currently the Chair of the Scientific Advisory Board of the Lymphoma Research Foundation. He has also authored, or co-authored, over 400 scientific publications, and was the founding editor of the Journal of Clinical Oncology.

John S. Macdonald, M.D.image

John S. Macdonald, MD, is Chief Medical Officer for Aptium Oncology Inc. He served as Medical Director and Chief of Gastrointestinal Oncology at St. Vincent’s Comprehensive Cancer Center in New York City from 1998-2007.  Dr Macdonald is Board certified in internal medicine and oncology. In addition to his responsibilities at the Saint Vincent’s Cancer Center from 1998 to 2007, Dr. Macdonald served as Chief of Medical Oncology at St. Vincent’s Hospital and Medical Center, and Professor of Medicine at the New York Medical College.

Dr. Macdonald was named as the first recipient of an endowed professorship, the Lynn Wood Neag Distinguished Professor of Gastrointestinal Oncology, in 1999.  He is recognized as a leading educator in Medical Oncology and has received numerous forms of recognition for his skills in medical education including being honored as Outstanding Clinical Attending Physician by the Department of Medicine at Georgetown University in 1977 and serving as a member of the Medical Oncology Section of the American Board of Internal Medicine from 1987 to 1993.

A leader in his field and a specialist in gastrointestinal cancer, as well as a member of numerous professional organizations including the American College of Physicians, American Association for Cancer Research and American Society of Clinical Oncology, Dr. Macdonald has over 400 papers and chapters and has been an editor of several books. He has provided well over 400 presentations both nationally and internationally and has authored more than 300 articles which have been published in many medical journals, including The New England Journal of Medicine, Cancer; Recent Results in Cancer Research; Advances in Medical Oncology, Research, and Education; and Medscape Hematology-Oncology.  In addition to his writing he has served as editor of multiple journals including Cancer Treatment Reports, Journal of Clinical Oncology, and the Manual of Oncologic Therapeutics. In 2007 he served as editor of Advances in the Management of gastric Cancer.

Dr. Macdonald received his medical degree from Harvard Medical School. He then went on to complete an internship and residency in internal medicine at the Beth Israel Hospital in Boston, and was awarded a fellowship in oncology at the National Cancer Institute. He was awarded an American Cancer Society Junior Faculty Fellowship.

Dr. Macdonald has received numerous awards and distinctions including being named in the Best Doctors in America listing in Good Housekeeping’s “Best 300 Doctors in America.” He has been named one of New York Magazine’s “Best Doctors in New York” over the last seven years.

Christopher J. Logothetis, M.D.image

Dr. Christopher J. Logothetis is Director of the Genitourinary Cancer Center and Director of the Prostate Cancer Research Program, which have integrated more than 60 faculty from 7 departments in clinical and basic research studies in prostate cancer.  He is the Principal Investigator of The University of Texas M. D. Anderson Cancer Center SPORE (Specialized Programs of Research Excellence) in Prostate Cancer, a 5-year, multidisciplinary, collaborative grant funded by the National Cancer Institute.  Dr. Logothetis has keen insight into the potential for change and the importance of collaborations among colleagues in academic medicine, community physicians, and patient support and advocacy communities.

Dr. Logothetis has a longstanding interest in genitourinary cancers—germ cell tumors, bladder, renal, and most recently in his career, prostate cancer.  His research experience preceded the development of effective chemotherapy and extends to the current era of molecular targeted therapies and classification of cancer.  He was among the first to test chemotherapy agents at a time of general skepticism that chemotherapy would be useful in advanced prostate cancer.

Dr. Logothetis has substantial experience both as an investigator in clinical and applied research and as a leader in multidisciplinary research programs.  He is the Bessie McGoldrick Professor of Medicine and Chairman of the Department of Genitourinary Medical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston, Texas.  He holds the Roy M. and Phyllis Gough Huffington Distinguished Chair in Clinical Research in Urologic Oncology. 

On the national level, Dr. Logothetis has been appointed to the Board of Scientific Advisors of the NCI and is a member of the External Advisory Committee for the NCI-sponsored project to characterize the human cancer genome.

Dr. Logothetis is a fervent proponent of improving the translational research environment to align clinical care with research goals.  The Center for Applied Research of Genitourinary Cancers reflects the success achieved by thoughtful physician and scientist recruitments, productive intramural and extramural collaborations; education and training of young investigators, and development of critical common resources.

Dr. Logothetis received his MD degree from the University of Athens (Greece) and completed internship and residency training at Cook County Hospital in Chicago.  On completion of his fellowship at M. D. Anderson Cancer Center, he joined the faculty.

Donald A. Berry, PhDimage

Donald Berry holds the Frank T. McGraw Memorial Chair for Cancer Research at The University of Texas M. D. Anderson Cancer Center, where he is Head of the Division of Quantitative Sciences and Chairman of the Department of Biostatistics. In addition, he serves as the faculty statistician on the Breast Cancer Committee of the Cancer and Leukemia Group B (CALGB), a national oncology group.

Through Berry Consultants, LLC he has consulted with many pharmaceutical and medical device companies on clinical trial design and analysis issues. He is well known as a developer of adaptive designs that minimize sample size while having a greater chance of detecting true signals of drug activity, efficiently using information that accrues over the course of the trial. He is also co- developer (with Giovanni Parmigiani) of BRCAPRO, a widely used program that provides individuals’ probabilities of carrying mutations of breast and ovarian cancer susceptibility genes BRCA1 and BRCA2.

Dr. Berry received his Ph.D. in statistics from Yale University, and previously served on the faculty at the University of Minnesota and at Duke University, where he held the Edger Thompson Professorship in the College of Arts and Sciences. Dr. Berry is the author of about 300 published articles as well as several books on biostatistics. Dr. Berry has been the principal investigator for numerous medical research programs funded by the National Institutes of Health, the National Cancer Institute, and the National Science Foundation. He is a Fellow of the American Statistical Association and of the Institute of Mathematical Statistics.

Neil Spector, M.D. image
Dr. Spector, with 20 years of oncology experience, serves as Director of Translational Research in Oncology on Duke University Medical Center’s cancer drug development team. He also serves as Co-Director of the Experimental Therapeutics Program in the cancer center. Prior to joining Duke, Dr. Spector served as Director of GlaxoSmithKline’s Exploratory Medical Sciences in Oncology, where he successfully developed two important cancer drugs, Tykerb (lapatinib) and Nelarabine (ara-G analog), from the bench to the clinic and then guided them through Food and Drug Administration (FDA) approval.

Dr. Spector received his medical degree from New Jersey Medical School, UMDNJ. He completed his internship and residency at University of Texas - Southwestern Parkland Memorial Hospital. His teaching experience also includes seven years at the Dana-Farber Cancer Institute in Boston and five years as an Assistant Professor of Medicine at the University of Miami.